Home > News > Altair Nanotechnologies Testing RenaZorb With 2nd Pharm. Co.
January 27th, 2003
Altair Nanotechnologies Testing RenaZorb With 2nd Pharm. Co.
Abstract:
Altair Nanotechnologies Inc. (Nasdaq:ALTI) announced that it has entered into a testing agreement with a second pharmaceutical company for in vivo (animal) evaluation of RenaZorb(TM), its new pharmaceutical candidate for phosphate control in kidney dialysis patients.
Source:
BusinessWire
| Related News Press |
Nanomedicine
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
|
|
||
|
|
||
| The latest news from around the world, FREE | ||
|
|
||
|
|
||
| Premium Products | ||
|
|
||
|
Only the news you want to read!
Learn More |
||
|
|
||
|
Full-service, expert consulting
Learn More |
||
|
|
||